Previous 10 | Next 10 |
Gainers: GeoVax Labs ( GOVX ) +42% . InflaRx ( IFRX ) +37% . Sunshine Biopharma ( SBFM ) +35% . Nutriband ( NTRB ) +29% . Talaris Therapeutics ( TALS ) +24% . Chimerix ( CMRX ) +20% . Liberty TripAdvisor Holdings ...
Gainers: Sunshine Biopharma ( SBFM ) +26% . InflaRx IFRX +14% . Talaris Therapeutics ( TALS ) +8% . Nutriband ( NTRB ) +7% . Biodesix ( BDSX ) +5% . Losers: Revelation Biosciences REVB -52% . Virax Biolabs VR...
Gainers: Inspira Technologies Oxy ( IINN ) +98% . Cano Health CANO +18% . Veru VERU +16% . Amylyx Pharmaceuticals ( AMLX ) +13% . Equillium ( EQ ) +12% . Losers: Applied Molecular Transport AMTI -26% . HTG Molecular D...
Morgan Stanley has downgraded Talaris Therapeutics ( NASDAQ: TALS ) to hold from buy amid late-stage results for its kidney transplant drug that indicate safety concerns. The firm has a $8 price target (~248% upside based on Friday's close). Despite the downgrade, shar...
Gainers: Alpha Tau Medical ( DRTS ) +42% . Precigen ( PGEN ) +20% . Amylyx Pharmaceuticals ( AMLX ) +18% . bluebird bio ( BLUE ) +13% . Talaris Therapeutics ( TALS ) +11% . Losers: Revelation Biosciences ( REVB ...
Gainers: Allena Pharmaceuticals ( ALNA ) +46% . Mega Matrix ( MTMT ) +43% . Faraday Future Intelligent Electric ( FFIE ) +30% . Tyra Biosciences ( TYRA ) +29% . Omeros ( OMER ) +28% . Clovis Oncology ( CLVS ) +22% . ...
Gainers: Accolade ( ACCD ) +18% . Clovis Oncology ( CLVS ) +18% . Larimar Therapeutics ( LRMR ) +14% . Tyra Biosciences ( TYRA ) +13% . VectivBio Holding ( VECT ) +13% . Losers: Talaris Therapeutics ( TALS ) -48% . Agile Therapeu...
Talaris Therapeutics ( NASDAQ: TALS ) said that its kidney transplant drug, FCR001, was successful in helping patients to wean off chronic anti-rejection drugs in a phase 3 trial . In an update, Talaris said that 24 patients have been enrolled in the trial. Three ...
All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date have achieved and mainta...
A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...
News, Short Squeeze, Breakout and More Instantly...
Talaris Therapeutics Inc. Company Name:
TALS Stock Symbol:
NASDAQ Market:
Combined Company to Trade on Nasdaq Under Ticker “TRML” Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) today announced the results of the special...
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris” or the “C...
NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) announced today NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, a...